{"id":48528,"date":"2022-09-19T13:02:02","date_gmt":"2022-09-19T11:02:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/"},"modified":"2022-09-19T13:02:02","modified_gmt":"2022-09-19T11:02:02","slug":"onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/","title":{"rendered":"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference"},"content":{"rendered":"
\n

SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc.<\/a>, a clinical-stage biotechnology company focused on the development of novel cancer interventions, today announced that Chief Medical Officer Kartik Krishnan, MD, PhD, will present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.\n<\/p>\n

<\/a><\/p>\n

\nDr. Krishnan will be participating in the panel discussion, \u201cPredictive Biomarkers, Sequencing and Diagnostics, Oh My!\u201d at 9:50 am ET.\n<\/p>\n

\nFor more information or to schedule a one-on-one meeting with Dr. Krishnan, CEO Martin Driscoll and CFO Matthew Head at the meeting, please contact your Cantor representative directly or contact OncoNano at https:\/\/onconano.com\/#contact<\/a>.\n<\/p>\n

\nAbout OncoNano Medicine
\n
<\/b>OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery and a platform of immune-oncology therapeutics that activate and guide the body\u2019s immune system to target cancer.\n<\/p>\n

\nOncoNano\u2019s lead development candidate is pegsitacianine, a novel fluorescent nanoprobe, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. ONM-501, OncoNano\u2019s second development program, is a next generation STING (ST<\/b>imulator of IN<\/b>terferon G<\/b>enes) agonist that is advancing towards a first in human trial in the first half of 2023. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at www.OncoNano.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMacDougall
\n
Lauren Arnold
\n
781-235-3060
\n
larnold@macbiocom.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc., a clinical-stage biotechnology company focused on the development of novel cancer interventions, today announced that Chief Medical Officer Kartik Krishnan, MD, PhD, will present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. Dr. Krishnan … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48528","6":"format-standard","7":"category-industry"},"yoast_head":"\nOncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc., a clinical-stage biotechnology company focused on the development of novel cancer interventions, today announced that Chief Medical Officer Kartik Krishnan, MD, PhD, will present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. Dr. Krishnan ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-19T11:02:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220919005099\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference\",\"datePublished\":\"2022-09-19T11:02:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/\"},\"wordCount\":292,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005099\\\/en\\\/827960\\\/21\\\/Onconano_Horizontal_Logo_full_color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/\",\"name\":\"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005099\\\/en\\\/827960\\\/21\\\/Onconano_Horizontal_Logo_full_color.jpg\",\"datePublished\":\"2022-09-19T11:02:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005099\\\/en\\\/827960\\\/21\\\/Onconano_Horizontal_Logo_full_color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005099\\\/en\\\/827960\\\/21\\\/Onconano_Horizontal_Logo_full_color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/","og_locale":"en_US","og_type":"article","og_title":"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference - Pharma Trend","og_description":"SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc., a clinical-stage biotechnology company focused on the development of novel cancer interventions, today announced that Chief Medical Officer Kartik Krishnan, MD, PhD, will present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. Dr. Krishnan ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-19T11:02:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220919005099\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference","datePublished":"2022-09-19T11:02:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/"},"wordCount":292,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220919005099\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/","url":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/","name":"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220919005099\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg","datePublished":"2022-09-19T11:02:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220919005099\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220919005099\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-to-present-at-cantor-fitzgerald-oncology-hemonc-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48528"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48528\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}